Cite
HARVARD Citation
Pal, S. et al. (2021). A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 397 (10275), pp. 695-703. [Online].